Open AccessCisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma
Author(s) -
Giorgio Perilongo,
Rudolf Maibach,
Elisabeth Shafford,
Laurence Brugières,
Penelope Brock,
Bruce Morland,
Beatriz de Camargo,
József Zsíros,
Derek Roebuck,
Arthur Zimmermann,
Daniël C. Aronson,
Margaret Childs,
Eva Widing,
Véronique Laithier,
J. Plaschkes,
Jon Pritchard,
Marcello Scopinaro,
Gordon A. MacKinlay,
Piotr Czauderna
Publication year - 2009
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0810613
Subject(s) - medicine , cisplatin , hepatoblastoma , confidence interval , doxorubicin , surgery , chemotherapy , urology , gastroenterology
Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom